



- (51) **International Patent Classification:**
C07K 16/10 (2006.01) *A61P 31/14* (2006.01)
- (21) **International Application Number:**
PCT/IB2024/061257
- (22) **International Filing Date:**
12 November 2024 (12.11.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/598,807 14 November 2023 (14.11.2023) US
- (71) **Applicant:** JANSSEN PHARMACEUTICALS, INC.
[US/US]; 1125 TRENTON-HARBOURTON ROAD, TI-
TUSVILLE, New Jersey 08560 (US).
- (72) **Inventors:** KOLKMAN, Joost; Archimedesweg 4, 2333
CN Leiden (NL). VAN SCHERPENZEEL, Revina Ca-
mara; Turnhoutseweg 30, 2340 Beerse (BE). JACOBS,
Steven; 920 US Route 202, P.O. Box 300, Raritan, New
Jersey 08869 (US). GEOGHEGAN, James; 7 Lucent Drive,
Lebanon, New Hampshire 03766 (US). RAPPAZZO,

Garrett; 7 Lucent Drive, Lebanon, New Hampshire 03766
(US).

- (74) **Agent:** LANE, David A. et al.; JOHNSON & JOHNSON,
One Johnson & Johnson Plaza, New Brunswick, New Jersey
08933 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

- (54) **Title:** ANTI-RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES AND USES THEREOF




FIG. 2A

- (57) **Abstract:** Provided herein are antibodies and antigen binding fragments thereof that specifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for the prevention, treatment, and diagnoses of viral infections and/or treatment of one or more symptoms of RSV-mediated disease.

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*